Advertisement

Prostate Cancer

  • Daniel R. Henderson
  • Nicholas van AsEmail author
Chapter
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)

Abstract

The use of choline-PET/CT (C-PET/CT) in prostate radiotherapy planning has been evaluated in two principal settings: patient selection for treatment and target volume delineation. Choline-based tracers are used, as the relatively low glucose metabolism of prostate cancer means FDG-based tracers perform poorly [1].

Keywords

Prostate Cancer Insufficient Evidence Localise Prostate Cancer Stereotactic Radiotherapy Bone Involvement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013;40(Suppl 1):S5–10.CrossRefPubMedGoogle Scholar
  2. 2.
    Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59(1):51–60.CrossRefPubMedGoogle Scholar
  3. 3.
    Evangelista L, Guttilla A, Zattoni F, Muzzio PC. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol. 2013;63(6):1040–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64(1):106–17.CrossRefPubMedGoogle Scholar
  5. 5.
    Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014;9:135.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Jereczek-Fossa BA, Rodari M, Bonora M, Fanti P, Fodor C, Pepe G, et al. [11C]choline PET/CT impacts treatment decision making in patients with prostate cancer referred for radiotherapy. Clin Genitourin Cancer. 2014;12(3):155–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Souvatzoglou M, Krause BJ, Purschel A, Thamm R, Schuster T, Buck AK, et al. Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol. 2011;99(2):193–200.CrossRefPubMedGoogle Scholar
  8. 8.
    Tree A, Jones C, Sohaib A, Khoo V, van As N. Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method? Radiat Oncol. 2013;8(1):228.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N, et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys. 2008;72(3):799–807.CrossRefPubMedGoogle Scholar
  10. 10.
    Van den Bergh L, Koole M, Isebaert S, Joniau S, Deroose CM, Oyen R, et al. Is there an additional value of (1)(1)C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? Int J Radiat Oncol Biol Phys. 2012;83(5):1486–92.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Clinical OncologyThe Royal Marsden NHS Foundation TrustLondonUK

Personalised recommendations